Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G, Giamberardino M A, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S
Most patients treated with erenumab in clinical practice have chronic migraine (CM). We assessed the rate and possible predictors of conversion from CM to episodic migraine (EM) in a real-life study.
